Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.
Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, Carrato A, Costello E, Navarro P. Martinez-Bosch N, et al. Among authors: visa l. Oncotarget. 2018 Aug 31;9(68):32984-32996. doi: 10.18632/oncotarget.26034. eCollection 2018 Aug 31. Oncotarget. 2018. PMID: 30250644 Free PMC article.
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.
Martínez-Bosch N, Cristóbal H, Iglesias M, Gironella M, Barranco L, Visa L, Calafato D, Jiménez-Parrado S, Earl J, Carrato A, Manero-Rupérez N, Moreno M, Morales A, Guerra C, Navarro P, García de Frutos P. Martínez-Bosch N, et al. Among authors: visa l. EBioMedicine. 2022 Jan;75:103797. doi: 10.1016/j.ebiom.2021.103797. Epub 2021 Dec 29. EBioMedicine. 2022. PMID: 34973624 Free PMC article.
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C. Sampera A, et al. Among authors: visa l. Mol Cancer Ther. 2019 Nov;18(11):2135-2145. doi: 10.1158/1535-7163.MCT-19-0455. Epub 2019 Sep 4. Mol Cancer Ther. 2019. PMID: 31484705
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L. Maurel J, et al. Among authors: visa l. Cancer Chemother Pharmacol. 2018 Dec;82(6):935-943. doi: 10.1007/s00280-018-3682-9. Epub 2018 Sep 17. Cancer Chemother Pharmacol. 2018. PMID: 30225601 Clinical Trial.
Solid cancer, antiphospholipid antibodies, and venous thromboembolism.
Font C, Vidal L, Espinosa G, Tàssies D, Monteagudo J, Farrús B, Visa L, Cervera R, Gascon P, Reverter JC. Font C, et al. Among authors: visa l. Autoimmun Rev. 2011 Feb;10(4):222-7. doi: 10.1016/j.autrev.2010.10.006. Epub 2010 Oct 16. Autoimmun Rev. 2011. PMID: 20955822 Review.
50 results